"An orthogonal analysis was performed using a qPCR EML4-ALK fusion detection kit. ALK fusion prevalence is very similar for Chile (3.67%, N=2142), Brazil (4.05%, N=1013) and Peru (4.59%,
N=675). Whereas a comparison between OFA and SofC assays showed similar sensitivity, OFA had significantly higher specificity and higher positive predictive value, which opens new opportunities for a more specific determination of ALK gene rearrangements."
J Mol Diagn. 2021 Sep;23(9):1127-1137.
Multigene mutation detection contributes to the rapid screening of patients with lung adenocarcinoma who respond to targeted therapy.
Biomed Res Int. 2021 May 28;2021:9939065.
"We demonstrate the case of 62-year-old female non-smoker with high PD-L1 expression and BRAF V600E mutated NSCLC. The progression-free survival (PFS) of firstline combination of atezolizumab with platinum-based chemotherapy and sequential
second-line treatment with BRAFi Vemurafenib are 20 and 5.5 months, respectively."
Front Oncol. 2021 Jun 10;11:634920.
Compared with NGS, RT-PCR appears to be a reliable method of detecting EML4-ALK fusion in patients with NSCLC.
Mol Diagn Ther. 2021 Jun 16.
In KRAS-mutated CRC, exon 3 mutations predict the worst prognosis, while exon 4 mutations predict the best prognosis. Among KRAS exon 2 mutated patients, codon 13 mutations predict worse prognosis than codon 12 mutations. Mutations of different KRAS exons should be analyzed separately.
Journal of Cancer. 2021; 12(17): 5331-5337.
In this study, we discovered that PABPC1 is a prognostic biomarker and a therapeutic target for ESCC, particularly early-stage ESCC.
Cancer Manag Res. 2021 Jul 5;13:5361-5372.